Regulations.gov document
Exhibit A Guidance for FDA Staff and Industry Marketed Unapproved Drugs Compliance Policy…
Supporting & Related Material · FDA-2015-N-1355 · posted Dec 27, 2016
Key facts
| Document ID | FDA-2015-N-1355-0020 |
|---|---|
| Title | Exhibit A Guidance for FDA Staff and Industry Marketed Unapproved Drugs Compliance Policy Guide Sec. 440.100 Marketed New Drugs Without Approved NDAs or ANDAs Sept 9, 2011 re: Comment from Keller and Heckman LLP (Cetylite Industries, Inc.) |
| Document type | Supporting & Related Material |
| Subtype | Background Material |
| Agency | FDA |
| Docket | FDA-2015-N-1355 |
| Posted | Dec 27, 2016 |
At a glance
- 10–99 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: